SUO 2019 why should we care about surveillance practice, urologic cancer follow-up patients, effectiveness of guideline recommendations, ECOG status, M0 renal cell carcinoma, imaging for pT1a tumor follow-up.
SES AUA 2025 phase 1 trial of mevrometostat (PF-06821497), mevrometostat with enzalutamide plus ADT, abiraterone.
SES AUA 2025, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), ARASENS trial, Darolutamide, Androgen Deprivation Therapy (ADT), abiraterone, enzalutamide, cabazitaxel.
SES AUA 2025, prostate cancer, Veracyte, Active Surveillance for prostate cancer, SPOP mutations, PTEN mutations, PAM50.
SES AUA 2025 high-risk biochemically recurrent prostate cancer, enzalutamide monotherapy treatment, phase 3 EMBARK study, EMBARK (NCT02319837).
SES AUA 2025, prostate cancer, EMBARK trial, Leuprolide, biochemical recurrence in prostate cancer.
Ruchika Talwar interviews Apoorv Dhir and Rishi Sekar about their study on cancer-related financial hardship among cancer survivors. The researchers discuss findings from the HINTS-SEER…
Oliver Sartor and Kambiz Rahbar discuss the RaLu study examining the safety and efficacy of sequential radiopharmaceutical treatments in metastatic castration-resistant prostate cancer. The discussion…
Diane Newman delivers a presentation on pelvic floor muscle rehabilitation following radical prostatectomy, highlighting the prevalence and impact of post-surgical urinary incontinence. She explained that…
SES AUA 2025 mental health diagnoses in testicular cancer survivors, mental health disorder, orchiectomy for testicular cancer, Truven Marketscan Commercial Claims and Encounters database.
SES AUA 2025, urologic workforce shortage, coping mechanisms for urologists, stress management for urologists.
